This trial is active, not recruiting.

Condition breast cancer
Sponsor University of Michigan
Collaborator Damon Runyon Cancer Research Foundation
Start date November 2013
End date September 2016
Trial size 49 participants
Trial identifier NCT01983995, HUM00078882, UMCC 2013.098


Aromatase inhibitors are commonly prescribed for treatment of postmenopausal women with breast cancer. These medications can cause side effects in some women, and occasionally they can be quite bothersome. We are doing a study to better understand the side effects of aromatase inhibitors so that we can hopefully treat them better or possibly prevent them. In particular, we are interested in pain and difficulty sleeping. This study is designed to assess the effect of aromatase inhibitors on pain, sleep quality, and fatigue and the interplay of these side effects and their subsequent impact on daily activity. Each participant will fill out a series of questionnaires about pain, sleep quality, and fatigue and will also complete a sleep diary and wear an actigraphy watch for 10 days before starting an aromatase inhibitor and after taking it for 3 months. We hope to learn more about these symptoms so we can better manage medication toxicity in the future.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Postmenopausal women starting aromatase inhibitor therapy will undergo assessment with questionnaires and actigraphy before starting AI therapy and after 3 months of treatment.

Primary Outcomes

Feasibility of conducting an actigraphy study with breast cancer patients
time frame: 3 months

Secondary Outcomes

Association between patient-reported sleep quality, fatigue, and pain and objective actigraphy measurements.
time frame: 3 months
Change in pain, fatigue, sleep disturbance, and daytime activity with 3 months of aromatase inhibitor therapy
time frame: 3 Months

Eligibility Criteria

Female participants at least 50 years old.

Inclusion Criteria: - Female, aged 50 years or older, postmenopausal. - Patients with histologically proven stage 0-III invasive carcinoma of the breast that is estrogen receptor and/or progesterone receptor positive by immunohistochemical staining, who are planning to start treatment with a standard dose of aromatase inhibitor (AI) therapy. - Subjects must have undergone surgical resection of their primary tumor, as indicated. The most recent surgery must have been performed at least 4 weeks before the baseline evaluation and no additional surgeries (including reconstructive procedures) should be planned during study participation. - Cytoxic chemotherapy, if applicable, must have been completed at least 4 weeks before the baseline evaluation. - Radiation therapy, if applicable, must have been completed at least 2 weeks before baseline evaluation. - Eastern Cooperative Oncology Group performance status 0-2. - Ability to operate the accelerometer Exclusion Criteria: - Diagnosis of sleep apnea or restless leg syndrome. - Use of a wheelchair for ambulation most of the time. - Second or third shift workers or other non-traditional sleep schedules. - History of medical arthritic disease that could confound or interfere with evaluation of pain or activity level, including but not limited to inflammatory arthritis (rheumatoid arthritis, systemic lupus, spondyloarthropathy, psoriatic arthritis, polymyalgia rheumatica), Parkinson's disease, and cancer involving the bone. - Serious or unstable medical condition that could likely lead to hospitalization during the course of the study or compromise study participation

Additional Information

Official title Prospective Pilot Study Evaluating the Inter-relationships Between Sleep Disturbance, Fatigue, Pain, and Daytime Activity in Breast Cancer Patients Starting Aromatase Inhibitor Therapy
Principal investigator Norah L Henry, MD, PhD
Trial information was received from ClinicalTrials.gov and was last updated in May 2016.
Information provided to ClinicalTrials.gov by University of Michigan.